抗体药物偶联物（ADCs）结合了抗体的高特异性和小分子药物的强效细胞毒性，实现对癌细胞的精准靶向递送，同时减少对正常组织的损伤。该靶向策略不仅提升了治疗效果，还降低了全身毒性，使ADCs成为治疗难以靶向癌症的有前景的选择。
双特异性抗体药物偶联物（bsADC）通过同时靶向两种肿瘤相关抗原，旨在降低非肿瘤组织毒性并提升抗肿瘤效果。为助力新型bsADC的研发，我们团队构建了规模化bsADC发现平台，具备以下核心优势：
| Target(s) | Immunization |
|
CMC | Nonclinical | Phase I | Status |
| TROP2 x EGFR |
|
Partnered | ||||
| EGFR x MET |
|
Partnered | ||||
| HER3 x MUC1 |
|
Partnered | ||||
| HER2 x TROP2 |
|
Partnered | ||||
| EGFR x MUC1 |
|
Partnered | ||||
| PTK7 x B7-H3 |
|
Partnered | ||||
| EGFR x HER3 |
|
Partnered | ||||
| PTK7 x EGFR |
|
|||||
| PTK7 x TROP2 |
|
|||||
| SEZ6 x B7-H3 |
|
|||||
| HER3 x MET |
|
|||||
| HER3 x B7-H3 |
|
|||||
| DLL3 x B7-H3 |
|
|||||
| DLL3 x SEZ6 |
|
|||||
| FOLR1 x FOLR1 |
|
|||||
| MUC1 x TROP2 |
|
|||||
| FOLR1 x MUC1 |
|
|||||
| ITGB6 x B7-H3 |
|
|||||
| FOLR1 x MUC16 |
|
|||||
| HER3 x EPCAM |
|
|||||
| EGFR x 5T4 (TPBG) |
|
|||||
| 5T4 (TPBG) x MUC1 |
|
|||||
| TROP2 x NECTIN-4 |
|
|||||
| FAP x GPC1 |
|
|||||
| MET x B7-H3 |
|
|||||
| MET x EPCAM |
|
|||||
| MSLN x MSLN |
|
|||||
| LGR5 x EGFR |
|
|||||
| CDH6 x FOLR1 |
|
|||||
| MSLN x FOLR1 |
|
|||||
| MSLN x MUC1 |
|
|||||
| B7-H4 x FOLR1 |
|
|||||
| FAP x B7-H3 |
|
|||||
| FAP x TROP2 |
|
|||||
| FAP x CDCP1 |
|
|||||
| CDH17 x Claudin 18.2 |
|
|||||
| CDH17 x MET |
|
|||||
| TAA-targeting antibody backbones available for flexible plug & play | ||||||
| ADAM9 | AFP | AMHR2 | B7-H3 | B7-H4 | CAIX | CCR9 |
| CD105 | CD142 | CD155 | CD22 | CD30 | CD7 | CD70 |
| CDCP1 | CDH11 | CDH17 | CDH3 | CDH6 | CEACAM5 | CEACAM6 |
| Claudin 18.2 | CLDN3 | CLDN6 | CLEC12A | DDR1 | DLK1 | DR5 |
| EGFR | EPCAM | EPHA2 | EPHB2 | FAP | FLT3 | FOLR1 |
| GPC-1 | GUCY2C | HER2 | HER3 | HLA-G | HPN | IL3RA |
| ITGB6 | KIT | KREMEN2 | LGR5 | LIV-1 | LRRC15 | LUNX |
| LY6G6D | LYPD3 | MET | MSLN | MUC1 | MUC16 | MUC18 |
| Nectin-4 | PALP | PRLR | PSMA | PTK7 | ROR1 | SEZ6 |
| SLC34A2 | SSTR2 | TIM1 | 5T4(TPBG) | TROP2 | and more | |
百奥赛图与全球多家ADC企业达成了合作关系，包括IDEAYA、ABL Bio、Ona Therapeutics和ADC Therapeutics。联系我们，探索评估、许可或共同开发的机会！
